Related Experiment Video

Updated: Jul 19, 2026

Ferric Chloride-induced Murine Thrombosis Models
10:37

Ferric Chloride-induced Murine Thrombosis Models

Published on: September 5, 2016

Thrombin inhibitors and anti-factor Xa agents in the treatment of arterial occlusion

V Klauss1, M Spannagl

  • 1Department of Hemostaseology, Med. Klinik-Innenstadt, University of Munich, Ziemssenstr. 1, 80336 Munich, Germany. klauss@med.uni-muenchen.de

Current Drug Targets
|November 1, 2006
PubMed

Insights

Cardiovascular disease causes significant mortality. New anticoagulants like direct thrombin and anti-factor Xa agents show promise in managing arterial thrombosis and thrombotic complications, potentially overcoming limitations of unfractionated heparin.

Area of Science:

  • Cardiovascular Medicine
  • Hematology
  • Pharmacology

Background:

  • Cardiovascular disease is a primary cause of death and illness globally.
  • Arterial thrombosis, a key factor in cardiovascular events, stems from diverse causes like atherosclerosis and hypercoagulable states.
  • Current treatments, including platelet inhibitors, necessitate improved anticoagulation strategies.

Purpose of the Study:

  • To review the clinical data on novel anticoagulants for managing arterial thrombosis.
  • To evaluate the potential advantages of direct thrombin inhibitors and anti-factor Xa agents over unfractionated heparin.
  • To discuss optimal anticoagulation regimens in patients with coronary artery disease.

Main Methods:

  • Review of available clinical data on direct thrombin inhibitors and anti-factor Xa agents.
  • Analysis of efficacy and safety profiles of these novel anticoagulants.
  • Comparison with unfractionated heparin in the context of arterial thrombosis and percutaneous interventions.

Main Results:

  • Direct thrombin inhibitors and anti-factor Xa agents offer potential improvements over unfractionated heparin.
  • These agents may provide more predictable pharmacokinetics and reduced monitoring requirements.
  • Clinical data suggest efficacy in preventing thrombotic complications in coronary artery disease.

Conclusions:

  • Novel anticoagulants represent a significant advancement in managing arterial thrombosis.
  • Direct thrombin inhibitors and anti-factor Xa agents may offer a superior alternative to unfractionated heparin for certain patient populations.
  • Further research and clinical trials are warranted to establish optimal use and long-term benefits.

More Related Videos

Ferric Chloride-induced Thrombosis Mouse Model on Carotid Artery and Mesentery Vessel07:26

Ferric Chloride-induced Thrombosis Mouse Model on Carotid Artery and Mesentery Vessel

Published on: June 29, 2015

Related Concept Videos

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
Clot Retraction and Fibrinolysis01:16

Clot Retraction and Fibrinolysis

After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.